TICKERNOMICS Sign up
Last Update: 2023-12-23 06:01:01
CareDx Inc. ( CDNA ) https://www.caredx.com
11.69USD
Sector:
Healthcare
Industry:
Diagnostics & Research
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
CDNA
3.82%
SPY
30.72%
-84.70%
CDNA
SPY
112.82%
-41.64%
CDNA
SPY
201.04%
CDNA
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
533.66
376.67
0.71
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.90
1.80
1.35
-3.76
0.00
-4.59
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-42.84
63.49
-27.63
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.9872
-28.68
-22.90
1.48
Other Earnings and Cash Flow Stats:
CareDx Inc. ( CDNA ) Net Income TTM ($MM) is -82.50
CareDx Inc. ( CDNA ) Operating Income TTM ($MM) is -89.57
CareDx Inc. ( CDNA ) Owners' Earnings Annual ($MM) is 0.00
CareDx Inc. ( CDNA ) Current Price to Owners' Earnings ratio is 0.00
CareDx Inc. ( CDNA ) EBITDA TTM ($MM) is -72.49
CareDx Inc. ( CDNA ) EBITDA Margin is -27.63%
Capital Allocation:
CareDx Inc. ( CDNA ) has paid 0.00 dividends per share and bought back -0.689341 million shares in the past 12 months
CareDx Inc. ( CDNA ) has reduced its debt by 4.711 million USD in the last 12 months
Capital Structure:
CareDx Inc. ( CDNA ) Interest-bearing Debt ($MM) as of last quarter is 35
CareDx Inc. ( CDNA ) Annual Working Capital Investments ($MM) are -61
CareDx Inc. ( CDNA ) Book Value ($MM) as of last quarter is 394
CareDx Inc. ( CDNA ) Debt/Capital as of last quarter is 8%
Other Balance Sheet Stats:
CareDx Inc. ( CDNA ) has 75 million in cash on hand as of last quarter
CareDx Inc. ( CDNA ) has 72 million of liabilities due within 12 months, and long term debt 0 as of last quarter
CareDx Inc. ( CDNA ) has 54 common shares outstanding as of last quarter
CareDx Inc. ( CDNA ) has 0 million USD of preferred stock value
Academic Scores:
CareDx Inc. ( CDNA ) Altman Z-Score is 2.09 as of last quarter
CareDx Inc. ( CDNA ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
CareDx Inc. ( CDNA ) largest shareholder is Royce & Associates, LP owning 1061555 shares at 12.41 ($MM) value
Reginald Seeto(an insider) Sold 2818 shares of CareDx Inc. ( CDNA ) for the amount of $19472.38 on 2023-10-02
2.26% of CareDx Inc. ( CDNA ) is held by insiders, and 105.08% is held by institutions
CareDx Inc. ( CDNA ) went public on 2014-07-17
Other CareDx Inc. ( CDNA ) financial metrics:
FCF:-23.30
Unlevered Free Cash Flow:0.00
EPS:-1.73
Operating Margin:-42.84
Gross Profit Margin:63.49
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-23.83
Beta:1.48
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About CareDx Inc. ( CDNA ) :
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.